Corner Therapeutics
Corner Therapeutics aims to transform the standard of care by developing rapid, patient-friendly, and low-cost immunotherapies for difficult-to-treat diseases. They are pioneering a new class of multi-purpose immunotherapies that induce robust and durable immunity against cancers and infectious diseases through their versatile dendritic cell hyperactivation platform.
Industries
Nr. of Employees
small (1-50)
Corner Therapeutics
Products
mRNA-encoded adjuvant platform
A platform whereby mRNAs encode immunostimulatory proteins that are formulated in lipid nanoparticles to act as encoded adjuvants, intended to increase T cell memory responses when combined with antigen-encoding mRNAs.
Dendritic cell hyperactivation platform
A platform using hyperactivator molecules to induce a DC state that combines antigen presentation, co-stimulation, migration, polarization cytokine secretion and memory-signal release (IL-1β) to produce long-lived memory T and B cell responses.
DCITE
Dendritic Cell Initiated T cell Engineering platform that uses lipid nanoparticle formulations to deliver mRNA encoding cGASdeltaN to activate dendritic cells via the STING pathway.
CRN-1001
A dendritic cell hyperactivator and vaccine adjuvant that enhances antigen presentation, co-stimulation, inflammatory cytokine secretion, and T cell immunity.
mRNA-encoded adjuvant platform
A platform whereby mRNAs encode immunostimulatory proteins that are formulated in lipid nanoparticles to act as encoded adjuvants, intended to increase T cell memory responses when combined with antigen-encoding mRNAs.
Dendritic cell hyperactivation platform
A platform using hyperactivator molecules to induce a DC state that combines antigen presentation, co-stimulation, migration, polarization cytokine secretion and memory-signal release (IL-1β) to produce long-lived memory T and B cell responses.
DCITE
Dendritic Cell Initiated T cell Engineering platform that uses lipid nanoparticle formulations to deliver mRNA encoding cGASdeltaN to activate dendritic cells via the STING pathway.
CRN-1001
A dendritic cell hyperactivator and vaccine adjuvant that enhances antigen presentation, co-stimulation, inflammatory cytokine secretion, and T cell immunity.
Services
Development and delivery workflows for patient-specific vaccines intended to generate rapid, durable T cell and antibody responses; emphasis on short lead times and low-cost production.
Service or capability to combine mRNA-encoded adjuvant LNPs with existing mRNA-LNP antigen constructs to enhance cellular and humoral immunogenicity.
Development and delivery workflows for patient-specific vaccines intended to generate rapid, durable T cell and antibody responses; emphasis on short lead times and low-cost production.
Service or capability to combine mRNA-encoded adjuvant LNPs with existing mRNA-LNP antigen constructs to enhance cellular and humoral immunogenicity.
Expertise Areas
- Dendritic cell biology and immunotherapy
- Inflammasome and IL-1β signaling in antigen-presenting cells
- mRNA vaccine and LNP-based adjuvant development
- Personalized cancer vaccine design
Key Technologies
- Lipid nanoparticle (LNP) mRNA delivery
- mRNA-encoded protein adjuvants
- Inflammasome activation (e.g., NLRP3-related pathways)
- cGAS-STING pathway modulation (referenced)